François‐Xavier Mahon

Author

Also Known As

F X Mahon, F Xavier Mahon, F. X. Mahon, F.-X. Mahon, F.X. Mahon, F.‐X. Mahon, Francois-Xavier Mahon, Francois-xavier Mahon, Francois‐Xavier Mahon, François-Xavier Mahon

366

Publications

12.6K

Citations

H-Index

Concepts

All Affiliations

Inserm Institut Bergonié Université de Bordeaux Hôpital Saint-Louis Centre Hospitalier Universitaire de Bordeaux

About

François‐Xavier Mahon is an author at Inserm specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	29	3.6K
2	Health Sciences	11	11	2.3K
3	Engineering	2	2	139
4	Biostatistics	1	1	32
5	Blood Transplantation	1	1	27

François‐Xavier Mahon

130

Publications

11.2K

Citations

H-Index

Page 1

	Year	Citations
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, The Lancet Oncology Hematological MalignancyOncologyChronic Myeloid LeukaemiaHematologyMyeloid Neoplasia	2010	1.5K
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Stéphane Picard, Karine Titier, Gabriel Étienne, Blood	2006	604
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models François‐Xavier Mahon, Françis Belloc, Valérie Lagarde, Blood	2003	537
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Philippe Rousselot, Françoise Huguet, Delphine Réa, Blood	2006	528
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Journal of Clinical Oncology Hematological MalignancyStop ImatinibChronic Myeloid LeukemiaPurpose ImatinibMedicine	2016	484
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon, JNCI Journal of the National Cancer Institute	2011	424
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Journal of Clinical Oncology	2013	405
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia Claude Preudhomme, Joëlle Guilhot, Franck E. Nicolini, New England Journal of Medicine	2010	382
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Blood	2011	314

Page 1